Clinical Trials
23 trialsNCT06801834 2026-05-20
EVOKE-SCLC-04
Gilead Sciences
Phase 3 Recruiting
NCT06203210 2026-03-02
IDeate-Lung02
Daiichi Sankyo
Phase 3 Recruiting
NCT07365241 2026-01-26
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Not yet recruiting
NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT01904253 2024-09-05
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
Taiho Oncology, Inc.
Phase 2 Terminated
NCT02481830 2023-07-27
CheckMate331
Bristol-Myers Squibb
Phase 3 Completed
NCT01033032 2022-05-03
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00286169 2022-04-12
Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)
Sumitomo Pharma Co., Ltd.
Phase 3 Terminated
NCT03253068 2020-05-19
Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
Wakayama Medical University
Phase 2 Unknown
NCT00388960 2019-11-19
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
Celgene
Phase 2 Completed
NCT00547651 2019-11-06
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
Celgene
Phase 3 Completed
NCT00915083 2019-11-01
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
Celgene
Phase 1 Completed
NCT00375193 2019-10-24
Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
Celgene
Phase 2 Completed
NCT01364727 2019-04-16
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Stanford University
Phase 2 Completed
NCT01355705 2018-09-18
Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Stanford University
Phase 1/2 Completed
NCT01331824 2018-04-23
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT01259375 2017-04-17
ARSARC-PI-0010
University of Utah
Phase 2 Completed
NCT01076504 2016-05-05
A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00890955 2015-12-23
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
Hoosier Cancer Research Network
Phase 1 Completed
NCT00660504 2014-07-18
Phase3 Study of Amrubicin With Cisplatin Versus Etoposide-cisplatin for Extensive Disease Small Cell Lung Cancer
Sumitomo Pharma (Suzhou) Co., Ltd.
Phase 3 Completed
NCT00132054 2013-05-30
Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00319969 2009-09-30
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
Celgene
Phase 2 Completed
NCT00380835 2008-09-23
Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer
Celgene
Phase 2 Withdrawn